Technical Analysis for AKCA - Akcea Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 16.38 -8.59% -1.54
AKCA closed down 8.59 percent on Thursday, February 27, 2020, on 1.37 times normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical AKCA trend table...

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
BB Squeeze Ended Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
50 DMA Resistance Bearish -8.59%
Crossed Above 20 DMA Bullish -8.59%
Pocket Pivot Bullish Swing Setup -8.59%
Spinning Top Other -8.59%
Bollinger Band Squeeze Range Contraction -8.59%
Earnings Movers Other -8.59%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company's volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company's clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).
Biopharmaceutical Medical Specialties Cardiology Dyslipidemia Lipids Low Density Lipoprotein Antisense RNA Lipid Disorders Lipoprotein Lipase Deficiency Lipoproteins Familial Chylomicronemia Syndrome Familial Partial Lipodystrophy

Is AKCA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 34.04
52 Week Low 13.9
Average Volume 277,472
200-Day Moving Average 19.91
50-Day Moving Average 18.03
20-Day Moving Average 17.65
10-Day Moving Average 17.61
Average True Range 0.98
ADX 11.09
+DI 19.24
-DI 23.19
Chandelier Exit (Long, 3 ATRs ) 16.23
Chandelier Exit (Short, 3 ATRs ) 19.26
Upper Bollinger Band 18.74
Lower Bollinger Band 16.56
Percent B (%b) -0.08
BandWidth 12.33
MACD Line -0.22
MACD Signal Line -0.13
MACD Histogram -0.0888
Fundamentals Value
Market Cap 1.05 Billion
Num Shares 63.9 Million
EPS -1.89
Price-to-Earnings (P/E) Ratio -8.67
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.29
Resistance 3 (R3) 18.49 18.07 17.97
Resistance 2 (R2) 18.07 17.58 17.96 17.86
Resistance 1 (R1) 17.22 17.28 17.01 17.02 17.76
Pivot Point 16.80 16.80 16.69 16.69 16.80
Support 1 (S1) 15.95 16.31 15.74 15.75 15.00
Support 2 (S2) 15.53 16.01 15.42 14.90
Support 3 (S3) 14.68 15.53 14.79
Support 4 (S4) 14.48